# Vertex (VRTX) net assets (shareholders' equity)

URL: https://funkfolio.com/stock/VRTX/net-assets

> Vertex Pharmaceuticals (VRTX) net assets (shareholders' equity) were $18.67B at the end of fiscal 2025, up 13.7% from fiscal 2024.

---

## Vertex Pharmaceuticals (VRTX) net assets (shareholders' equity)

**Net assets · fiscal 2025:** $18.67B at Dec 31, 2025

Vertex Pharmaceuticals (VRTX) had net assets of $18.67B at the end of fiscal 2025 (December 31, 2025). That is 13.7% higher than the $16.41B of fiscal 2024. Figures as of 18 Nov 2026, 20:02 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Net assets, fiscal 2025:** $18.67B
- **Change on fiscal 2024:** +13.7%
- **Growth, 5 years:** +16.5% a year
- **Growth, 10 years:** +34.8% a year
- **Highest on record:** $18.67B fiscal 2025
- **Lowest on record:** $238.87M fiscal 2008
- **Fiscal years on record:** 18 2008–2025

Figures as of 18 Nov 2026, 20:02 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Vertex Pharmaceuticals net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 16.5% a year; over ten years the rate was 34.8% a year. Across the 18 fiscal years on record (2008–2025), the highest was $18.67B in fiscal 2025 and the lowest $238.87M in fiscal 2008.

### Net assets by fiscal year

### Vertex Pharmaceuticals net assets (shareholders' equity), year by year

Vertex Pharmaceuticals (VRTX) net assets (shareholders' equity) by fiscal year

| Fiscal year | Net assets | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $18.67B | 13.7% up | Dec 31, 2025 |
| 2024 | $16.41B | 6.7% down | Dec 31, 2024 |
| 2023 | $17.58B | 26.4% up | Dec 31, 2023 |
| 2022 | $13.91B | 37.7% up | Dec 31, 2022 |
| 2021 | $10.10B | 16.3% up | Dec 31, 2021 |
| 2020 | $8.69B | 42.8% up | Dec 31, 2020 |
| 2019 | $6.09B | 37.2% up | Dec 31, 2019 |
| 2018 | $4.44B | 118.6% up | Dec 31, 2018 |
| 2017 | $2.03B | 75.4% up | Dec 31, 2017 |
| 2016 | $1.16B | 23.0% up | Dec 31, 2016 |
| 2015 | $939.97M | 12.6% down | Dec 31, 2015 |
| 2014 | $1.08B | 20.7% down | Dec 31, 2014 |
| 2013 | $1.36B | 35.8% up | Dec 31, 2013 |
| 2012 | $999.18M | 27.0% up | Dec 31, 2012 |
| 2011 | $786.84M | 56.1% up | Dec 31, 2011 |
| 2010 | $503.97M | 54.0% down | Dec 31, 2010 |
| 2009 | $1.10B | 359.0% up | Dec 31, 2009 |
| 2008 | $238.87M | — | Dec 31, 2008 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

### How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

### Net assets at health care companies of similar size

Net assets of Vertex Pharmaceuticals and comparable companies

| Company | Net assets | Fiscal year |
| --- | --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/net-assets) | $86.48B | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/net-assets) | $52.53B | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/net-assets) | $17.82B | 2025 |
| Vertex Pharmaceuticals VRTX | $18.67B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/net-assets) | $49.46B | 2026 |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/net-assets) | $18.47B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals earnings](https://funkfolio.com/stock/VRTX/earnings)
- [Vertex Pharmaceuticals earnings per share (EPS)](https://funkfolio.com/stock/VRTX/eps)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals P/B ratio](https://funkfolio.com/stock/VRTX/pb-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals cash on hand](https://funkfolio.com/stock/VRTX/cash)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals total liabilities](https://funkfolio.com/stock/VRTX/total-liabilities)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals net assets (shareholders' equity): questions and answers

**What are Vertex Pharmaceuticals's net assets?**

Vertex Pharmaceuticals (VRTX) had net assets of $18.67B at the end of fiscal 2025 (December 31, 2025). That is 13.7% higher than the $16.41B of fiscal 2024.

**What is the growth rate of Vertex Pharmaceuticals's net assets?**

Over the five fiscal years to 2025 net assets grew at a compound 16.5% a year; over ten years the rate was 34.8% a year.

**What are the highest and lowest net assets figures on record for Vertex Pharmaceuticals?**

Across the 18 fiscal years on record (2008–2025), the highest was $18.67B in fiscal 2025 and the lowest $238.87M in fiscal 2008.

**How is Vertex Pharmaceuticals's net assets calculated?**

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Vertex Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: net assets (shareholders' equity)

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.
